Anti-c-ErbB2/c-Neu (Ab-2) Mouse mAb (9G6)

Anti-c-ErbB2/c-Neu (Ab-2), mouse monoclonal, clone 9G6, recognizes the ~185 kDa c-ErbB2/c-Neu SK-BR-3 cells and breast carcinoma. It is validated for IP and IHC on frozen and paraffin sections.

Purified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with SP2/0 Ag14 mouse myeloma cells. Recognizes the ~185 kDa c-ErbB2/c-neu protein.

Recognizes the ~185 kDa c-ErbB2/c-Neu in SK-BR-3 cells and breast carcinoma tissue. Does not cross-react with v-ErbB2 or the EGF receptor.

Human

cells overexpressing human c-ErbB2/c-Neu

Frozen Sections (5 µg/ml)

Immunoprecipitation (1 µg/sample)

Paraffin Sections (see application references)

Lyophilized from a volatile buffer, 100 µg BSA.

Reconstitute the lyophilized antibody with sterile PBS, pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 µg/ml. Lyophilized antibodies should be reconstituted at 4°C with occasional gentle mixing for at least 2 h. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage with 0.1% azide. Avoid freeze/thaw cycles of solutions.

Negative Control
HepG2 cells or normal skin

Positive Control
SK-BR-3 cells or breast carcinoma tissue

Immunoprecipitates the ~185 kDa c-neu protein and has been reported to stain formalin-fixed paraffin-embedded tissue sections of human breast carcinomas overexpressing the c-neu protein. This antibody reacts with a cell surface epitope of c-neu but does not cross-react with the EGF receptor. In one study ductal carcinomas in situ displaying large-cell, comedo growth type, were stained while none of 16 ductal carcinomas in situ of small-cell, papillary, or cribiform growth type were stained by this antibody. Antibody should be titrated for optimal results in individual systems.

Van De Vijver, M.J., et al.1988 New Engl. J. Med.319, 1239.
DiFiore, P.P., et al.1987 Science237, 178.
Slamon, D.J., et al. 1987 Science235, 177.
Varley, J.M., et al.1987 Oncogene1, 423.
Bargmann, C.I., et al. 1986 Nature319, 226.
Yamamoto, T., et al.1986 Nature319, 230.
Blick, M., et al. 1984 Blood64, 1234.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)